Gilda Bontempo

机构：ViiV Healthcare (Spain)

发表论文 14 篇 · 总被引 270 次 · h-index 8

代表论文

• Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial (2022 · Clinical Infectious Diseases · 被引 172)
• Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants (2023 · Antimicrobial Agents and Chemotherapy · 被引 20)
• Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings (2024 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 17)
• Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations (2024 · Journal of the International AIDS Society · 被引 12)
• Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies (2024 · AIDS Research and Therapy · 被引 11)
• 1584. CARISEL A Hybrid III Implementation Effectiveness Study of implementation of Cabotegravir plus Rilpivirine Long Acting (CAB+RPV LA) in EU Health Care Settings Key Clinical and Implementation Outcomes by Implementation Arm (2022 · Open Forum Infectious Diseases · 被引 11)